Skip to Content
Merck
CN

95102433

BEAS-2B Cell Line human

NOTE: Both the cell line and DNA from the cell line may be available for this product. Please choose -1VL or VIAL for cells, or -DNA-5UG for DNA.

Sign Into View Organizational & Contract Pricing

Select a Size


About This Item

UNSPSC Code:
41106514
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

biological source

human lung

Quality Level

description

Human bronchial epithelium, normal

form

liquid

packaging

tube of 5 μg 95102433-DNA-5UG
pkg of vial of cells 95102433-1VL

growth mode

Adherent

karyotype

Not specified

morphology

Epithelial-like

products

Not specified

receptors

Not specified

technique(s)

cell culture | mammalian: suitable

Application

BEAS-2B Cell line has been used to study differentiation of squamous cells and effect of biological and chemical agents on differentiation.

Biochem/physiol Actions

BEAS-2B cells were derived from normal bronchial epithelium obtained from autopsy of non-cancerous individuals. Cells were infected with a replication-defective SV40/adenovirus 12 hybrid and cloned. Squamous differentiation can be observed in response to serum. This ability can be used for screening chemical and biological agents inducing or affecting differentiation and/or carcinogenesis. The cell line has been applied for studies of pneumococcal infection mechanisms. BEAS-2B was described to express keratins and SV40 T antigen. Subculturing the cells before confluency is necessary as confluent cultures rapidly undergo squamous terminal differentiation.
Human bronchial epithelium, normal
STR-PCR Data: Amelogenin: X,Y
CSF1PO: 9,12
D13S317: 13
D16S539: 12
D5S818: 12,13
D7S820: 10,13
THO1: 7,9.3
TPOX: 6,11
vWA: 17,18

Packaging

NOTE: Both the cell line and DNA from the cell line may be available for this product. Please choose -1VL or VIAL for cells, or -DNA-5UG for DNA.

Preparation Note

BEGM, also known as LHC-9 with modification (available from Clonetics Corporation, CC3171 (BEBM) plus additives CC4175 or BEGM Bullet Kit, CC3170); Note: Additives supplied contain gentamycin which has been omitted for culture at ECACC; media is serum-free.
Passage sub-confluent cultures using 0.25% trypsin or trypsin/EDTA. Incubate at room temperature for 5-10 min until cells detach. Add fresh medium and disperse cells, centrifuge and resuspend pellet in medium. Seed into new flasks at 1500 to 3000 cells per cm2. Flasks have to be precoated with a mixture of 0.01 mg/ml fibronectin, 0.03 mg/ml collagen and 0.001 mg/ml bovine serum albumin dissolved in BEGM. Add mixture at ratio of 0.2 ml per cm2 surface area. Incubate at 5% CO2, 37°C for at least 6 hours at 37oC. Remove excess fluid and allow flasks to dry by incubating at 37oC overnight, leaving the caps loose. Prior to addition of cells wash flask three times with PBS. Note: BEGM medium is almost serum-free, therefore trypsin inhibitor is essential. Add an equal or greater volume of trypsin inhibitor as trypsin used before, centrifuge and reseed cells in collagen coated flasks using culture medium.

Other Notes

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
Cultures from HPA Culture Collections and supplied by Sigma are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line.
Please view the Terms & Conditions of Supply for more information.

Disclaimer

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Storage Class Code

10 - Combustible liquids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The Expression of the Ubiquitin Ligase SIAH2 (Seven In Absentia Homolog 2) Is Increased in Human Lung Cancer
Paula Moreno
PLoS ONE (2015)
R Garcia-Villar et al.
British journal of pharmacology, 118(5), 1253-1261 (1996-07-01)
1. This study tested the hypothesis that a nitric oxide synthase (NOS) was activated in guinea-pig ileum in vitro in response to substance P (SP), and attempted to characterize the tachykinin receptor involved in this activation by the use of
L Teng et al.
The Journal of pharmacology and experimental therapeutics, 280(3), 1432-1444 (1997-03-01)
Lobeline is currently being developed as a substitution therapy for tobacco smoking cessation. Activation of CNS dopamine (DA) systems results in the reinforcing properties of nicotine. The present study compared the effects of lobeline and nicotine on rat striatum. Both
Andrea Marcellini et al.
European journal of pharmacology, 893, 173839-173839 (2020-12-29)
Inhaled corticosteroids (ICS) are recommended treatments for all degrees of asthma severity and in combination with bronchodilators are indicated for COPD patients with a history of frequent exacerbations. However, the long-term side effects of glucocorticoids (GCs) may include increased risk
Yu-Jung Lin et al.
Heliyon, 9(9), e20011-e20011 (2023-10-09)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused 403 million cases of coronavirus disease (COVID-19) and resulted in more than 5.7 million deaths worldwide. Extensive research has identified several potential drug treatments for COVID-19. However, the development of new

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service